NRX Pharmaceuticals (NRXP) EBIT (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported EBIT for 10 consecutive years, with -$6.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 74.4% year-over-year to -$6.5 million in Q2 2026; TTM through Jun 2026 was -$19.9 million, a 52.67% decrease from a year earlier, with the FY2025 full-year figure at -$16.2 million, up 12.31% from the prior year.
• EBIT was -$6.5 million for Q2 2026 at NRX Pharmaceuticals, down from -$4.7 million in the prior quarter.
• Over five years, EBIT peaked at -$2.4 million in Q4 2024 and troughed at -$15.7 million in Q1 2022.
• A 5-year average of -$6.3 million and a median of -$5.3 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT jumped 81.33% in 2022 and slumped 90.13% in 2025, its largest moves.
• Over 5 years, EBIT stood at -$9.9 million in 2022, then surged by 55.44% to -$4.4 million in 2023, then soared by 44.8% to -$2.4 million in 2024, then tumbled by 90.13% to -$4.6 million in 2025, then plunged by 40.68% to -$6.5 million in 2026.
• The last three EBIT figures came in at -$6.5 million (Q2 2026), -$4.7 million (Q1 2026), and -$4.6 million (Q4 2025), per Business Quant data.